Sera Prognostics, Inc. (SERA)
USD 8.18
(-0.37%)
USD 8.18
(-0.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 39.91 Million USD | -15.33% |
| 2022 | 45.72 Million USD | 29.03% |
| 2021 | 35.44 Million USD | 97.05% |
| 2020 | 17.98 Million USD | 8.49% |
| 2019 | 16.57 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 8.86 Million USD | 3.67% |
| 2024 Q2 | 8.9 Million USD | 0.47% |
| 2023 Q1 | 11.36 Million USD | 9.05% |
| 2023 FY | 38.71 Million USD | -15.33% |
| 2023 Q3 | 8.18 Million USD | -28.87% |
| 2023 Q2 | 11.5 Million USD | 1.2% |
| 2023 Q4 | 8.55 Million USD | 4.53% |
| 2022 Q2 | 11.76 Million USD | -4.47% |
| 2022 Q1 | 12.31 Million USD | -1.92% |
| 2022 Q4 | 10.42 Million USD | -7.07% |
| 2022 FY | 45.72 Million USD | 29.03% |
| 2022 Q3 | 11.21 Million USD | -4.68% |
| 2021 Q2 | 7.39 Million USD | 22.54% |
| 2021 FY | 35.44 Million USD | 97.05% |
| 2021 Q4 | 12.55 Million USD | 32.83% |
| 2021 Q1 | 6.03 Million USD | 26.82% |
| 2021 Q3 | 9.45 Million USD | 27.89% |
| 2020 Q2 | 4.28 Million USD | -0.28% |
| 2020 Q1 | 4.29 Million USD | 0.0% |
| 2020 Q4 | 4.75 Million USD | 2.39% |
| 2020 FY | 17.98 Million USD | 8.49% |
| 2020 Q3 | 4.64 Million USD | 8.42% |
| 2019 FY | 16.57 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 73.209% |
| Prenetics Global Limited | 60.73 Million USD | 34.279% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -145.311% |
| CareDx, Inc | 277.76 Million USD | 85.629% |
| Exact Sciences Corporation | 2.06 Billion USD | 98.063% |
| Exagen Inc. | 52.29 Million USD | 23.667% |
| Inotiv, Inc. | 246.9 Million USD | 83.833% |
| Guardant Health, Inc. | 901.62 Million USD | 95.573% |
| Biodesix, Inc. | 77.41 Million USD | 48.44% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -917.49% |
| Precipio, Inc. | 13.63 Million USD | -192.69% |
| iSpecimen Inc. | 16.27 Million USD | -145.232% |
| Natera, Inc. | 938.98 Million USD | 95.749% |
| Aspira Women's Health Inc. | 24.11 Million USD | -65.535% |
| Standard BioTools Inc. | 113.48 Million USD | 64.827% |
| 23andMe Holding Co. | 420.73 Million USD | 90.513% |
| Castle Biosciences, Inc. | 242.78 Million USD | 83.559% |
| Personalis, Inc. | 128.14 Million USD | 68.85% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 63.884% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -142.116% |
| OpGen, Inc. | 30.65 Million USD | -30.201% |
| T2 Biosystems, Inc. | 41.49 Million USD | 3.801% |
| Myriad Genetics, Inc. | 600.1 Million USD | 93.348% |
| ICON Public Limited Company | 755.64 Million USD | 94.717% |
| NeoGenomics, Inc. | 341.25 Million USD | 88.303% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -145.311% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 96.347% |
| RadNet, Inc. | 268.87 Million USD | 85.154% |
| MDxHealth SA | 71.25 Million USD | 43.981% |
| Psychemedics Corporation | 11.33 Million USD | -252.188% |
| Illumina, Inc. | 3.81 Billion USD | 98.953% |
| Check-Cap Ltd. | 19.28 Million USD | -106.963% |
| Twist Bioscience Corporation | 354.18 Million USD | 88.73% |
| DarioHealth Corp. | 62.17 Million USD | 35.797% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 76.78% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -279.413% |
| OPKO Health, Inc. | 574.68 Million USD | 93.054% |
| Medpace Holdings, Inc. | 187.68 Million USD | 78.731% |
| Neogen Corporation | 405.23 Million USD | 90.15% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -240.915% |
| Prenetics Global Limited | 60.73 Million USD | 34.279% |
| Mainz Biomed B.V. | 27.15 Million USD | -47.0% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -355.422% |
| Trinity Biotech plc | 46.49 Million USD | 14.148% |
| Neuronetics, Inc. | 82.25 Million USD | 51.474% |
| Sotera Health Company | 300.46 Million USD | 86.715% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -355.422% |